Related Experiment Videos
Rheumatoid arthritis: supplemental L-cysteine in penicillamine treatment--a controlled study
The Journal of Rheumatology
|June 1, 1985
Abstract
No abstract available in PubMed .
Related Concept Videos
Articles linked to this work by shared authors, journal, and citation graph.
Effects of proinsulin C-peptide on nitric oxide, microvascular blood flow and erythrocyte Na+,K+-ATPase activity in diabetes mellitus type I.
Clinical science (London, England : 1979)·2000
Reconstruction and visualization of irregularly sampled three- and four-dimensional ultrasound data for cerebrovascular applications.
Ultrasound in medicine & biology·2000
[Predictive genetic investigations. Individualization of diagnosis and treatment in families with multiple endocrine neoplasia type II].
Deutsche medizinische Wochenschrift (1946)·2000
[Polyglandular autoimmune syndrome type II: epidemiology and forms of manifestation].
Deutsche medizinische Wochenschrift (1946)·2000
Rethinking Anti-CD20 Therapies: From Fixed to Precision Dosing.
The Journal of rheumatology·2026
Remission rates of patients with axial spondyloarthritis in a tertiary care center.
The Journal of rheumatology·2026
Uncovering heterogeneous health burden in axial spondyloarthritis through latent class analysis of the ASAS health index.
The Journal of rheumatology·2026
Mendelian randomisation for rheumatology: beyond hype-what it's good for, what it can't do, and how to read it critically.
The Journal of rheumatology·2026
Seasonal variation in the office and ambulatory blood pressure control in patients treated with two dual antihypertensive therapies.
Hypertension research : official journal of the Japanese Society of Hypertension·2026
Multisystem infection with cavernous sinus thrombosis in seropositive rheumatoid arthritis: a clinico-radiological case report.
Annals of medicine and surgery (2012)·2026
Temporal Mapping of CSVD-Related White Matter Lesions and Concurrent Neurovascular Dysfunction in Spontaneously Hypertensive Rats.
CNS neuroscience & therapeutics·2026